Immunotherapy for Dogs: Still Running Behind Humans

Area of Science:

• Veterinary Oncology
• Immunology
• Comparative Medicine

Background:

• Effective cancer immunotherapies for dogs lag significantly behind human advancements.
• Treatments like CAR-T and NK-cell infusions are limited in canines by high costs, complex logistics, and a lack of identified target antigens.
• Development of monoclonal antibodies is hindered by insufficient knowledge of canine-specific antigens and their mechanisms of action.

Purpose of the Study:

• To identify and discuss the primary obstacles impeding the progress of canine cancer immunotherapy.
• To highlight areas requiring further research and development to advance veterinary cancer treatments.
• To provide a perspective on how to bridge the gap between human and canine immunotherapy.

Main Methods:

• Review of current literature on canine cancer immunotherapy.
• Analysis of challenges associated with translating human immunotherapies to canine applications.
• Identification of knowledge gaps in canine immunology and antigen discovery.

Main Results:

• Significant barriers exist for canine CAR-T and NK-cell therapies, including cost, logistics, and antigen identification.
• Limited understanding of canine target antigens complicates the development of monoclonal antibodies.
• Cancer's inherent immunosuppressive nature and chemotherapy's effects hinder the efficacy of immunogenic vaccines in dogs.

Conclusions:

• Veterinary cancer immunotherapy faces substantial hurdles related to cost, technical complexity, and fundamental biological knowledge.
• Further research into canine-specific antigens and the tumor microenvironment is crucial.
• Overcoming these challenges is essential for improving cancer treatment options for dogs, aligning them with human therapeutic advancements.